SurModics Inc. (SRDX)

72.80
NASDAQ : Health Technology
Prev Close 72.80
Day Low/High 70.83 / 73.40
52 Wk Low/High 25.00 / 82.35
Avg Volume 102.30K
Exchange NASDAQ
Shares Outstanding 13.35M
Market Cap 972.03M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent.

Surmodics To Webcast Third Quarter Fiscal 2018 Earnings Conference Call On August 6

Surmodics To Webcast Third Quarter Fiscal 2018 Earnings Conference Call On August 6

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2018 conference call on Monday, August 6, at...

Surmodics Announces Leadership Change And Appointment Of Interim CFO

Surmodics Announces Leadership Change And Appointment Of Interim CFO

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018.

Surmodics Acquires Thrombectomy Technology Assets From Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics Acquires Thrombectomy Technology Assets From Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative thrombectomy platform technology and...

Surmodics Reaches Analyst Target Price

In recent trading, shares of Surmodics Inc have crossed above the average analyst 12-month target price of $41.62, changing hands for $42.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

CORRECTING And REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

CORRECTING And REPLACING Surmodics Reports Second Quarter Fiscal 2018 Results, Increases Fiscal 2018 Guidance

The fifth bullet in the Recent Highlights section should read: EPS of $0.11, Non-GAAP EPS of $0.

Surmodics To Webcast Second Quarter Fiscal 2018 Earnings Conference Call On May 2

Surmodics To Webcast Second Quarter Fiscal 2018 Earnings Conference Call On May 2

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2018 conference call on Wednesday, May 2,...

Surmodics Announces FDA Clearance Of A New .018" Low-Profile PTA Balloon Dilation Catheter

Surmodics Announces FDA Clearance Of A New .018" Low-Profile PTA Balloon Dilation Catheter

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.

Surmodics To Present At Upcoming Investor Conferences

Surmodics To Present At Upcoming Investor Conferences

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at...

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and...

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018...

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and...

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017 conference...

Surmodics Announces First Patient Enrolled In TRANSCEND Pivotal Clinical Trial For SurVeil® Drug-Coated Balloon

Surmodics Announces First Patient Enrolled In TRANSCEND Pivotal Clinical Trial For SurVeil® Drug-Coated Balloon

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in TRANSCEND, the pivotal clinical trial for the SurVeil ®...

Surmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter

Surmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.

Six-Month Data From The Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

Six-Month Data From The Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company's SurVeil ® drug-coated...

Surmodics Reports Third Quarter Fiscal 2017 Results And Updates Fiscal 2017 Guidance

Surmodics Reports Third Quarter Fiscal 2017 Results And Updates Fiscal 2017 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 third quarter, ended June 30, 2017.

Surmodics Receives IDE Approval To Initiate Pivotal Trial Of The SurVeil™ Drug-Coated Balloon

Surmodics Receives IDE Approval To Initiate Pivotal Trial Of The SurVeil™ Drug-Coated Balloon

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.

Surmodics To Webcast Third Quarter 2017 Earnings Conference Call On August 3

Surmodics To Webcast Third Quarter 2017 Earnings Conference Call On August 3

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2017...

Surmodics To Present At Upcoming Investor Conferences

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017.

Surmodics To Webcast Second Quarter 2017 Earnings Conference Call On April 27

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2017...

Surmodics Appoints Lisa Wipperman Heine To Its Board Of Directors

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the addition of Lisa Wipperman Heine to the Company's Board of Directors,...

Surmodics to Present at Oppenheimer Healthcare Conference

Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

TheStreet Quant Rating: C (Hold)